Update on biologicals for treatment of juvenile idiopathic arthritis

Bibliography

• Petty RE, Southwood TR, Baum J, Revision of the proposed classification criteria for juvenile idiopathic arthritis: durban, 1997. J Rheumatol 1998;25:1991-4
   PubMedGoogle Scholar
• Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol 2002;29:1520-30
   PubMed Web of Science ®Google Scholar
• Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1992;4:754-9
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54(5):1390-400
   PubMed Web of Science ®Google Scholar
• Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother 2009;10:3049-60
   PubMed Web of Science ®Google Scholar
• Beukelman T, Patkar NM, Saag KG, 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465-82
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ruperto N, Ravelli A, Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9
   PubMed Web of Science ®Google Scholar
• Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002;29(5):1058-64
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008;58(5):1248-57
   PubMed Web of Science ®Google Scholar
• Moreland LW, Weinblatt ME, Keystone EC, Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33(5):854-61
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6):478-86
   PubMed Web of Science ®Google Scholar
• van de Putte LB, Rau R, Breedveld FC, Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003;Dec62(12):1168-7
   PubMed Web of Science ®Google Scholar
• Schiff MH, Burmester GR, Kent JD, Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65(7):889-94
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9
   PubMed Web of Science ®Google Scholar
• Horneff G, Ruperto N, Burgos-Vargas R, Effectiveness and safety of etanercept in paediatric subjects with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: the clipper study. Ann Rheum Dis 2012;71(Supple):424
   PubMedGoogle Scholar
• Lovell DJ, Reiff A, Jones OY, Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94
   PubMed Web of Science ®Google Scholar
• Horneff G, Schmeling H, Biedermann T, The German etanercept registry for treatment of Juvenile Idiopathic Arthritis (JIA). Ann Rheum Dis 2004;63:1638-44
   PubMed Web of Science ®Google Scholar
• Quartier P, Taupin P, Bourdeaut F, Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101
   PubMed Web of Science ®Google Scholar
• Horneff G, De Bock F, Foeldvari I, Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with Juvenile Idiopathic Arthritis (JIA). Preliminary data from the German JIA registry. Ann Rheum Dis 2009;68(4):519-25
   PubMed Web of Science ®Google Scholar
• Horneff G, Foeldvari I, Minden K, 10 years experience in the German JIA Etanercept Registry – lessons from changing patient populations. Arthritis Rheum (Munch) 2011;31:334-42
   Google Scholar
• Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4
   PubMed Web of Science ®Google Scholar
• Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatol (Oxford) 2011;50(1):214-21
   PubMed Web of Science ®Google Scholar
• Otten MH, Prince FH, Armbrust W, Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011;306(21):2340-7
   PubMed Web of Science ®Google Scholar
• Wallace CA, Giannini EH, Spalding SJ, For the childhood arthritis and rheumatology research alliance. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64(6):2012-21
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Horneff G. Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis. Rheumatol Int 2007;28(2):153-6
   PubMed Web of Science ®Google Scholar
• Prince FH, Twilt M, Jansen-Wijngaarden NC, van Suijlekom-Smit LW. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study. Ann Rheum Dis 2007;66(5):704-5
   PubMed Web of Science ®Google Scholar
• Horneff G, Ebert A, Fitter S, Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology 2009;48(8):916-19
   PubMed Web of Science ®Google Scholar
• Nielsen S, Ruperto N, Gerloni V, Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008;26(4):688-92
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Reiff A, Ilowite NT, Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58(5):1496-504
   PubMed Web of Science ®Google Scholar
• Horneff G, Foeldvari I, Minden K, Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatol (Oxford) 2011;50(1):230-6
   PubMed Web of Science ®Google Scholar
• Pontikaki I, Gerloni V, Gattinara M, Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis. Reumatismo 2006;58(1):31-8
   PubMedGoogle Scholar
• Quartier P, Taupin P, Bourdeaut F, Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101
   PubMed Web of Science ®Google Scholar
• van Dijken TD, Vastert SJ, Gerloni VM, Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2011;38:1441-6
   PubMed Web of Science ®Google Scholar
• Bloom BJ. Development of diabetes mellitus during etanercept therapy in a child with systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 2000;43:2606-8
   PubMed Web of Science ®Google Scholar
• Cron RQ, Beukelman T. Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA? Pediatr Rheumatol Online J 2010;8:23
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR, Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44(12):2862-9
   PubMed Web of Science ®Google Scholar
• Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-8
   PubMed Web of Science ®Google Scholar
• Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology 2005;44:1008-11
   PubMed Web of Science ®Google Scholar
• Horneff G, Bischof S; German BIKER Registry collaborative group. Long-term safety of etanercept compared to methotrexate and combinations in children with juvenile idiopathic arthritis – data of the German BIKER-registry. Arthritis Rheum 2011;63(Supple):S97
   Google Scholar
• Beukelman T, Xie F, Chen L, On behalf of the Safety Assessment of Biological ThERapeutics (SABER) Collaboration. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; [Epub ahead of print]
   Google Scholar
• Diak P, Siegel J, La Grenade L, Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62(8):2517-24
   PubMed Web of Science ®Google Scholar
• Simard JF, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010;62(12):3776-82
   PubMed Web of Science ®Google Scholar
• Nordstrom BL, Mines D, Gu Y, Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologics. Arthritis Care Res 2012; In press
   Google Scholar
• Beukelman T, Haynes K, Curtis JR, Safety Assessment of Biological Therapeutics Collaboration. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64(4):1263-71
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Ruperto N, Goodman S, Pediatric Rheumatology Collaborative Study Group: Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359(8):810-20
   PubMed Web of Science ®Google Scholar
• Kingsbury D, Quartier P, Santra S, Safety and efficacy of adalimumab in children with active polyarticular juvenile idiopathic arthroitos aged 2 to < 4 years or > 4 years weighing < 15 kg. Ann Rheum Dis 2012;71(Suppl 3):428
   Google Scholar
• Heiligenhaus A, Niewerth M, Ganser G, German Uveitis in Childhood Study Group. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 2007;46:1015-19
   PubMed Web of Science ®Google Scholar
• Biester S, Deuter C, Michels H, Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-24
   PubMed Web of Science ®Google Scholar
• Tynjala P, Kotaniemi K, Lindahl P, Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008;47:339-44
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Cuttica R, Paediatric Rheumatology International Trials Organisation: Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Cuttica R, Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718-22
   PubMed Web of Science ®Google Scholar
• Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006;5:864.e1-2
   Google Scholar
• Smith JA, Thompson DJS, Whitcup SM, A randomised, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23
   PubMed Web of Science ®Google Scholar
• Lamot L, Bukovac LT, Vidovic M, The ‘head-to-head’ comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2011;29:131-9
   PubMed Web of Science ®Google Scholar
• Armbrust W, Kamphuis SS, Wolfs TW, Tuberculosis in a nine-year-old girl treated with Infliximab for systemic juvenile idiopathic arthritis. Rheumatology 2004;43:527-9
   PubMed Web of Science ®Google Scholar
• Choy EH, Hazleman B, Smith M, Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002;41(10):1133-7
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
   PubMed Web of Science ®Google Scholar
• Kay J, Matteson EL, Dasgupta B, Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis & Rheumatism 2008;4:964-75
   Google Scholar
• Ilowite N, Porras O, Reiff A, Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009;28:129-37
   PubMed Web of Science ®Google Scholar
• Lequerre T, Quartier P, Rosellini D, Interleukin-1 receptor antagonist (Anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67:302-8
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54
   PubMed Web of Science ®Google Scholar
• Nigrovic PA, Mannion M, Prince FH, Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum 2011;63:545-55
   PubMed Web of Science ®Google Scholar
• De Jager W, Vastert SJ, Noordman BJ, IL-1 Receptor antagonist restores IL18 NK cell axis in sysrtemic JIA. Ann Rheum Dis 2012;71(Suppl 3):71
   PubMedGoogle Scholar
• Gattorno M, Piccini A, Lasigliè D, The Pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008;58:1505-15
   PubMed Web of Science ®Google Scholar
• Zeft A, Hollister R, LaFleur B, Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009;15:161-4
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Gianinni EH, Kimura Y, Preliminary evidence for bioactivity of IL-1 trap. (Rilonacept), a long acting il-1 inhibitor, in systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum 2006;54:S325
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Kimura Y, Long-term safety and efficacy of Rilonacept in patients with systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum 2009;60:S768
   Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, For the Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25
   PubMed Web of Science ®Google Scholar
• Ruperto N, Quartier P, Wulffraat N, Paediatric Rheumatology International Clinical Trials Organisation. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012;64:557-67
   PubMed Web of Science ®Google Scholar
• Quartier P, Erguven M, Horneff G, IL-1β Inhibition with Canakinumab in patients with systemic juvenile idiopathic arthritis: efficacy and safety outcomes from a single dose, placebo-controlled study. Ann Rheum Dis 2012;71(Suppl 3):705
   Google Scholar
• Rupert N, Brunner H, Quartier P, Efficacy and safety of canakinumab, fully human anti-interleukin-1beta antibody, in systemic juvenile idiopathic arthritis. Ann Rheum Dis 2012;71(Suppl 3):705
   Google Scholar
• Woo P, Wilkinson N, Prieur AM, Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005;7:1281-8
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Rapid improvement of signs and symptoms associated with systemic juvenile idiopathic arthritis (sJIA) by interleukin-6 (IL-6) blockade-results of a Tocilizumab sJIA phase III clinical trial. Arthritis Rheum 2006;54:S327
   Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371(9617):998-1006
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Miyamae T, Long-term safety and efficacy of tocilizumab in patients with systemic Juvenile Idiopathic Arthritis (JIA) under the extension and long-term trials. Arthritis Rheum 2008;58:S631
   PubMedGoogle Scholar
• De Benedetti FB, Brunner H, Ruperto N, Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER trial. Arthritis Rheum 2010;62:S596
   Google Scholar
• Imagawa T, Ozawa R, Miyamae T, Efficacy and safety in 48-week treatment of Tocilizumab in children with polyarticular course juvenile idiopathic arthritis with polyarticular or oligoarticular onset. Ann Rheum Dis 2007;66(Suppl 2):110
   Google Scholar
• Cron RQ. A signal achievement in the treatment of arthritis. Arthritis Rheum 2005;52(8):2229-32
   PubMed Web of Science ®Google Scholar
• Kremer JM, Dougados M, Emery P, Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P, Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010;62:1792-802
   PubMed Web of Science ®Google Scholar
• Feito JG, Pereda CA. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists. J Clin Rheumatol 2009;15:363-5
   PubMed Web of Science ®Google Scholar
• Narvaez J, Diaz-Torne C, Juanola X, Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2009;68:607-8
   PubMed Web of Science ®Google Scholar
• Kasher-Meron M, Uziel Y, Amital H. Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report. Rheumatology (Oxford) 2009;48:445-6
   PubMed Web of Science ®Google Scholar
• Testa C-A-P, Feito J-G, Arquillo C-M. Rituximab: A promising alternative in the treatment of systemic onset rheumatoid idiopathic arthritis (soJIA) when anti-TNF fails. Ann-Rheum-Dis 2007;66(Suppl 2):Abs SAT0415
   Google Scholar
• Alexeeva EI, Valieva SI, Bzarova TM, Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 2011;30:1163-72
   PubMed Web of Science ®Google Scholar
• Jansson AF, Sengler C, Kuemmerle-Deschner J, B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol 2011;30:87-97
   PubMed Web of Science ®Google Scholar
• Klein A, Kaul I, Foeldvari I, Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German methotrexate registry. Arthritis Care Res (Hoboken) 2012;64(9):1349-56
   PubMed Web of Science ®Google Scholar
• Dueckers G, Guellac N, Arbogast M, German Society of Paediatric Rheumatology. [Evidence and consensus based treatment guidelines 2010 for juvenile idiopathic arthritis by the German Society of Paediatric Rheumatology]. Klin Padiatr 2011;223:386-94
   PubMed Web of Science ®Google Scholar